These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 29264583)

  • 1. Assessing the role of everolimus in reducing hepatocellular carcinoma recurrence after living donor liver transplantation for patients within the UCSF criteria: re-inventing the role of mammalian target of rapamycin inhibitors.
    Thorat A; Jeng LB; Yang HR; Yeh CC; Hsu SC; Chen TH; Poon KS
    Ann Hepatobiliary Pancreat Surg; 2017 Nov; 21(4):205-211. PubMed ID: 29264583
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical outcome in patients with hepatocellular carcinoma after living-donor liver transplantation.
    Choi HJ; Kim DG; Na GH; Han JH; Hong TH; You YK
    World J Gastroenterol; 2013 Aug; 19(29):4737-44. PubMed ID: 23922471
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-Term Effects of Everolimus-Facilitated Tacrolimus Reduction in Living-Donor Liver Transplant Recipients with Hepatocellular Carcinoma.
    Sapisochin G; Lee WC; Joo DJ; Joh JW; Hata K; Soin AS; Veldandi UK; Kaneko S; Meier M; Leclair D; Sunkara G; Jeng LB
    Ann Transplant; 2022 Nov; 27():e937988. PubMed ID: 36411723
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Can living donor liver transplantation offer similar outcomes to deceased donor liver transplantation using expanded selection criteria for hepatocellular carcinoma?
    Chen LP; Li C; Wen TF; Yan LN; Li B; Yang JY
    Pak J Med Sci; 2015; 31(4):763-9. PubMed ID: 26430399
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Living Donor Liver Transplantation Outcomes for Hepatocellular Carcinoma Beyond Milan or UCSF Criteria.
    Gunay Y; Guler N; Yaprak O; Dayangac M; Akyildiz M; Altaca G; Yuzer Y; Tokat Y
    Indian J Surg; 2015 Dec; 77(Suppl 3):950-6. PubMed ID: 27011489
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effectiveness of the Combination of Everolimus and Tacrolimus With High Dosage of Mizoribine for Living Donor-Related Kidney Transplantation.
    Yoshimura N; Nakao T; Nakamura T; Harada S; Koshino K; Suzuki T; Ito T; Nobori S; Ushigome H
    Transplant Proc; 2016 Apr; 48(3):786-9. PubMed ID: 27234736
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Examinations of Factors Influencing Survival of Liver Transplantation for Hepatocellular Carcinoma: A Single-Center Experience From Budapest.
    Piros L; Fehérvári I; Görög D; Nemes B; Szabó J; Gerlei Z; Végső G; Kóbori L; Máthé Z
    Transplant Proc; 2015 Sep; 47(7):2201-6. PubMed ID: 26361680
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Trough Levels of Everolimus Are Associated With Recurrence Rates of Hepatocellular Carcinoma After Liver Transplantation.
    Cholongitas E; Antoniadis N; Goulis I; Theocharidou E; Ιmvrios G; Giouleme O; Filis D; Mouloudi E; Akriviadis E; Fouzas I
    Transplant Proc; 2019 Mar; 51(2):450-453. PubMed ID: 30879564
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Salvage liver transplantation for recurrent hepatocellular carcinoma within UCSF criteria after liver resection.
    Liu F; Wei Y; Wang W; Chen K; Yan L; Wen T; Zhao J; Xu M; Li B
    PLoS One; 2012; 7(11):e48932. PubMed ID: 23145027
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Younger age and presence of macrovascular invasion were independent significant factors associated with poor disease-free survival in hepatocellular carcinoma patients undergoing living donor liver transplantation.
    Wai CT; Woon WA; Tan YM; Lee KH; Tan KC
    Transplant Proc; 2012 Mar; 44(2):516-9. PubMed ID: 22410059
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adequacy of Initial Everolimus Dose, With and Without Calcineurin Inhibitors, in Kidney Transplant Recipients.
    Felipe C; Ferreira A; Bessa A; Abait T; Perez JD; Casarini DE; Medina-Pestana J; Tedesco H
    Ther Drug Monit; 2018 Feb; 40(1):52-58. PubMed ID: 29271815
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Section 5. Further expanding the criteria for HCC in living donor liver transplantation: when not to transplant: SNUH experience.
    Lee KW; Yi NJ; Suh KS
    Transplantation; 2014 Apr; 97 Suppl 8():S20-3. PubMed ID: 24849825
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combination of FDG-PET and UCSF Criteria for Predicting HCC Recurrence After Living Donor Liver Transplantation.
    Hsu CC; Chen CL; Wang CC; Lin CC; Yong CC; Wang SH; Liu YW; Lin TL; Lee WF; Lin YH; Chan YC; Wu YJ; Eng HL; Cheng YF
    Transplantation; 2016 Sep; 100(9):1925-32. PubMed ID: 27306534
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and Efficacy of Everolimus Rescue Treatment After Pediatric Living Donor Liver Transplantation.
    Ueno T; Kodama T; Noguchi Y; Deguchi K; Nomura M; Saka R; Watanabe M; Tazuke Y; Bessho K; Okuyama H
    Transplant Proc; 2020; 52(6):1829-1832. PubMed ID: 32571711
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of everolimus on survival after liver transplantation for hepatocellular carcinoma.
    Kang I; Lee JG; Choi SH; Kim HJ; Han DH; Choi GH; Kim MS; Choi JS; Kim SI; Joo DJ
    Clin Mol Hepatol; 2021 Oct; 27(4):589-602. PubMed ID: 34293849
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Optimal dose of everolimus administered with tacrolimus in living donor kidney transplantation.
    Hiramitsu T; Tomosugi T; Futamura K; Okada M; Goto N; Ichimori T; Narumi S; Watarai Y
    Int Immunopharmacol; 2019 Oct; 75():105772. PubMed ID: 31376625
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predictors of Outcome of Living Donor Liver Transplantation for Hepatocellular Carcinoma.
    Zakaria HM; Sallam AN; Ayoub II; Saleh SM; Maher D; Omar H; Abou-Shady M; Salama IA; Soliman EA; Abou El-Ella K; Ibrahim TM; Hammad EM
    Indian J Surg; 2017 Aug; 79(4):299-307. PubMed ID: 28827903
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison between living donor liver transplantation recipients who met the Milan and UCSF criteria after successful downstaging therapies.
    Lei J; Yan L
    J Gastrointest Surg; 2012 Nov; 16(11):2120-5. PubMed ID: 22948843
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Experience of using everolimus in the early stage of living donor liver transplantation.
    Jeng LB; Thorat A; Hsieh YW; Yang HR; Yeh CC; Chen TH; Hsu SC; Hsu CH
    Transplant Proc; 2014 Apr; 46(3):744-8. PubMed ID: 24767339
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intention-to-treat analysis of liver transplantation for hepatocellular carcinoma: living versus deceased donor transplantation.
    Bhangui P; Vibert E; Majno P; Salloum C; Andreani P; Zocrato J; Ichai P; Saliba F; Adam R; Castaing D; Azoulay D
    Hepatology; 2011 May; 53(5):1570-9. PubMed ID: 21520172
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.